Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Athena Oncology is a national network of independent, physician-led community oncology practices united by a shared commitment to preserving and strengthening high-quality cancer care close to home. Athena brings together practices across the country to collaborate, share expertise, and leverage collective resources while each member practice retains its full clinical autonomy and individual identity within its local community.

Through strategic collaboration, shared analytics, and pharmaceutical aggregation that responsibly leverages the collective scale of its member practices, Athena Oncology supports members in advancing clinical excellence, improving operational efficiency, and expanding patient access to innovative therapies. By aligning purchasing power and operational insights, Athena helps independent practices remain competitive while continuing to serve their local communities.

By connecting physician leaders, data experts, and partners across the oncology ecosystem, Athena Oncology creates a platform for independent practices to work together, exchange best practices, and sustain the long-term viability of community-based cancer care in the United States.

Blueprint Medicines, a Sanofi Company, is a global precision therapy company that aims to invent transformative medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, we seek to create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate our scientific innovation into a broad pipeline of important approved and investigational precision therapies aimed at addressing difficult-to-treat cancers and blood disorders. Today, we are delivering our approved medicines to patients in the United States, Europe and in other geographies ourselves or through our partners.

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.

Canopy is the leader in Enterprise AI for Oncology, providing practices with a unified platform for all the care that happens between visits and across patient services. Supporting ~10% of oncology providers in the U.S. across 500+ sites of care nationwide, Canopy enables practices to identify and prioritize patients who need help, resolve their issues using AI-native tools, and generate new reimbursement streams. For more information, visit www.canopycare.ai.

Cencora, formerly AmerisourceBergen, empowers oncology physician practices and ensures their patients have access to the most innovative and cost-effective specialty care close to home. Through our ION Oncology Practice Network GPO and Oncology Supply specialty distribution, along with our portfolio of integrated Specialty Solutions, we are a unified team of specialty practice partners, committed to building on our legacy of best-in-class service with meaningful innovation that supports our customers as they improve communities through patient-centric care.

We are now Cencora and are uniting our 46,000+ team members under one identity in pursuit of a shared purpose: our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #10 on the Global Fortune 500 with more than $200 billion in annual revenue. Learn more at www.Cencora.com.

At Daiichi Sankyo, we create essential medicine for longer, better lives. Every day, we strive to put our skills at the service of those most in need. By uniting cutting-edge science and technology with a genuine interest in people, we develop high-quality, life-changing solutions for the patients of today and tomorrow with great care and unwavering dedication. We rely on reason, ingenuity, perseverance and empathy to make bold strides in oncology.

Eisai Inc. is a human health care (hhc) company dedicated to pursuing innovative research and simplifying the treatment journey to help improve the lives of people affected by cancer, Alzheimer’s disease and other neurodegenerative conditions. Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.

Our hhc mission is the shared purpose that connects us to those we serve. It creates a network of powerful relationships that enable us to identify, understand and address unmet needs and healthcare disparities as we work towards achieving societal good.

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Our U.S. operations include discovery, research and development; manufacturing; global supply and logistics; and commercial activities.

To learn more, please visit https://us.eisai.com and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn and X) and oncology (LinkedIn and X) pages.

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth

Forus is an AI platform for medication access, used by thousands of providers across the U.S. to navigate prior authorization, affordability, and fulfillment for prescription medicines. Across millions of prescriptions annually, Forus is working to ensure that when a doctor decides a patient needs medication, nothing stands in the way.

With over 30 years of oncology leadership, Genentech is working toward a future where people with cancer can thrive. We deliver transformative therapies designed for lasting outcomes, pushing boldly for innovations that reach patients wherever they receive care. By working in lockstep with the medical, scientific, and patient communities, we are helping to shape the next era of cancer care.

Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. Genmab is recognized for its expertise in antibody science. The company continues to advance its late-stage pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients. Visit Genmab.com, LinkedIn and X.

Geron is a biopharmaceutical company that is charting a new course with the goal to deliver innovative treatment options for people living with blood cancer. Our tireless pursuit to improve outcomes for these patients resulted in the U.S. approval of the first ever telomerase inhibitor for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. As the sole company with an oligonucleotide telomerase inhibitor approved by the FDA, we feel a deep urgency to bring the potential power of telomerase inhibition to patients in need. We are conducting research in other blood cancers with high unmet need beyond LR-MDS, with ongoing clinical trials across other hematologic malignancies, including a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF). We are proud of the impact this Nobel-winning science is having in the fight against blood cancers. At Geron, we are united by a shared purpose: Every individual in every role can meaningfully contribute to our mission to change lives by changing the course of blood cancer. With a culture rooted in courage and determination, we will continue to innovate and pursue new possibilities for patients.

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer.

Ipsen is a global biopharmaceutical company focused on innovation and specialty care, At Ipsen, we develop and commercialize medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Disease. Our focus in oncology is on some of the most difficult-to-treat cancers. We have a growing portfolio of therapies for solid tumors and in hematology aimed at improving the lives of people living with pancreatic cancer, gastrointestinal and pancreatic neuroendocrine tumors, and carcinoid syndrome. Every day, our more than 5,000 employees worldwide, including nearly 800 in North America, work diligently to improve lives around the world. For more information, please visit

www.ipsen.com/us

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases-often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. 

Johnson & Johnson is a global healthcare leader, committed to solving the toughest health challenges and transforming lives through research, development, manufacture and distribution of medicines and medical technologies. The company’s Innovative Medicine business advances breakthrough science and develops transformational treatments in areas like oncology, immunology, neuroscience, and cardiopulmonary. In MedTech, the company is focused on developing and delivering cardiovascular, surgery, and vision solutions. Visit jnj.com to learn more.

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com. 

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn.

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer.  The potential to bring new hope to people with cancer drives our purpose and our commitment.  As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

Navista is an oncology practice alliance that provides advanced services, technology and financial support to help community practices remain independent and fuel their growth. Our mission is to empower community practices to deliver personalized, patient-centered cancer care, close to home, while acting with the speed and agility cancer care deserves. Navista includes more than 50 practice sites delivering multidisciplinary oncology and urology care nationwide. As a Cardinal Health company, we have the resources to invest in our alliance member practices for long-term success and help preserve each practice’s legacy of exceptional care. Together with our members, Navista unlocks the power of community oncology to help practices stay independent—for the good of their patients, practice and community. To learn more, visit Navista.com or follow us on LinkedIn.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram

Oncologic.ai is the category-defining Oncology Process Orchestration Platform™, purpose-built for community oncology, unifying agentic AI for diagnostics, therapy selection, prior authorization and workflow automation. Oncologic.ai helps practices reduce administrative burden, keep pace with rapidly evolving cancer science and accelerate time-to-therapy.

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs) and bispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. 

Company profile: We are a family-owned company innovating in iron metabolism, blood disorders, and cell cycle biology. With 700+ employees globally, we prioritize quality, collaboration, and  patient care to drive life-changing treatments.

Stemline Therapeutics, Inc. ("Stemline") a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Our dedicated team of scientists, specialists, researchers, and developers are committed to providing transformational oncology treatments to those who need them, with the ultimate goal of improving the lives of those impacted by cancer.

Syndax is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include a menin inhibitor and a monoclonal antibody that blocks the CSF-1 receptor. For more information, visit www.syndax.com or follow the Company on X and LinkedIn.

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere.  We ensure a tight connection from research to development to commercialization and rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to patients.  Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide.

Zydus Pharmaceuticals (USA) Inc. is part of Zydus Lifesciences Limited, a global life sciences company committed to improving access to high-quality medicines. Zydus operates in more than 50 countries and supports patients worldwide through a broad, growing portfolio of treatments and a global network of over 30 manufacturing facilities.

In the United States, Zydus is expanding its oncology presence with BeizrayTM (docetaxel injection), providing an exciting treatment option for patients receiving cancer care.